The geko device operates without the need for any external leg pressure. Credit: Sky Medical Technology / PRNewswire.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for the marketing of Sky Medical Technology’s new (W3) geko device variant.

The new device has been designed to increase microcirculatory blood flow in lower limb soft tissue in venous insufficiency and/or ischemia patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last year, the company also received FDA approval for its (W2) geko device for venous insufficiency and/or ischemia, which is related to the reduced flow of blood in the veins and arteries.

Non-invasive, wearable and easy to use, the geko device is the size of a wristwatch and can be worn at the knee.

It gently stimulates the common peroneal nerve and activates the calf and foot muscle pumps, which increases blood flow in the deep veins of the calf.

The company stated that the disposable device operates without the need for any external leg pressure and allows complete mobility.

It noted that the new (W3) geko device variant includes a third electrode, which enables significant nerve stimulation, as well as improved patient outcomes and comfort.

Additionally, the new device variant increases to two 12-hour therapeutic doses, from the two six-hour doses that the (W2) device provided.

Sky Medical Technology CEO and founder Bernard Ross said: “Achieving this latest 510(k) clearance for the geko device (W3) establishes Sky’s position as a leading innovator in MedTech dedicated to improving patient outcomes.

“Conditions such as venous insufficiency and ischemia are therapy areas sorely in need of innovation, and we are pleased to contribute to improvements in this care pathway that make recovery quicker, simpler and more comfortable.”